Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
09-11 April, 2025
Peptide Therapy SummitPeptide Therapy Summit
Not Confirmed
Not Confirmed
03-05 April, 2025
Not Confirmed
Not Confirmed
05-09 April, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
09-11 April, 2025
Peptide Therapy SummitPeptide Therapy Summit
Industry Trade Show
Not Confirmed
03-05 April, 2025
Industry Trade Show
Not Confirmed
05-09 April, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/our-unmatched-efficiency-and-track-record-of-faster-dmf-filings-give-our-customers-a-critical-competitive-advantage
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/molecular-glue-degraders-lilly-abbvie-sign-billion-dollar-deals-bms-leads-with-three-late-stage-drugs
20 Mar 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/dizals-golidocitinib-in-combination-with-anti-pd-1-shows-promise-in-io-resistant-non-small-cell-lung-cancer-302406882.html
07 Jan 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/us-fda-granted-priority-review-to-dizals-sunvozertinib-new-drug-application-302344065.html
11 Dec 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/dizal-announces-positive-pooled-data-of-sunvozertinib-in-egfr-tyrosine-kinase-inhibitor-resistant-non-small-cell-lung-cancer-published-in-lung-cancer-302328813.html
09 Dec 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-development-candidate-nomination-of-ide892-a-potential-best-in-class-mta-cooperative-prmt5-inhibitor-302325328.html
08 Nov 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/dizal-submits-new-drug-application-to-the-us-fda-for-sunvozertinib-in-treating-relapsed-or-refractory-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations-302299834.html
16 Sep 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/subgroup-analysis-from-pivotal-wu-kong1b-study-exhibits-robust-efficacy-of-sunvozertinib-in-non-small-cell-lung-cancer-patients-with-egfr-exon-20-insertion-mutations-across-different-baseline-characteristics-302250031.html
ABOUT THIS PAGE